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Abstract It was previously demonstrated that brief (≤1 h) exposures to echinocandins are as effective to kill Candida
albicans cells as continuous 24-h exposure. However, killing rates after continuous and short (1 h)
echinocandin exposures to C. albicans have not yet been evaluated in RPMI-1640 with and without 50 %
serum. We evaluated four echinocandin susceptible C. albicans bloodstream isolates, ATCC 10231 type strain
and an echinocandin-resistant isolate (DPL20, FKS F645P). Caspofungin MICs, time-kill and postantifungal
effect (PAFE) tests were performed in RPMI-1640 with and without 50 % serum. Killing rates (k values) in
time-kill and PAFE experiments were determined for each strain and concentration. In time-kill experiments,
colony count decreases were isolate- and concentration-dependent at 0.25, 1, 4, 8, 16 and 32 mg/L in
RPMI-1640, but concentration-independent at 1, 4, 8, 16 and 32 mg/L in 50 % serum. One-hour caspofungin
exposure at 4, 16 and 32 mg/L resulted in CFU decreases comparable with the results obtained in time-kill
experiments in RPMI-1640, but 50 % serum at 4, 16 and 32 mg/L allowed growth of all isolates (k values
were negative) (P < 0.05–0.001). PAFE in 50 % serum decreased markedly at 4, 16 and 32 mg/L. Killing
rates remained high and concentration-independent in 50 % serum in case of continuous but not in case of
brief caspofungin exposure. As only a short growth inhibition without killing was observed in 50 % serum,
clinical relevance of caspofungin PAFE in vivo is questionable.
Keywords (separated by '-') Echinocandins - Serum-based susceptibility testing - Postantifungal effect
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11 Abstract It was previously demonstrated that brief
12 (B1 h) exposures to echinocandins are as effective to
13 kill Candida albicans cells as continuous 24-h expo-
14 sure. However, killing rates after continuous and short
15 (1 h) echinocandin exposures to C. albicans have not
16 yet been evaluated in RPMI-1640 with and without
17 50 % serum. We evaluated four echinocandin suscep-
18 tible C. albicans bloodstream isolates, ATCC 10231
19 type strain and an echinocandin-resistant isolate
20 (DPL20, FKS F645P). Caspofungin MICs, time-kill
21 and postantifungal effect (PAFE) tests were performed
22 in RPMI-1640 with and without 50 % serum. Killing
23 rates (k values) in time-kill and PAFE experiments
24 were determined for each strain and concentration. In
25 time-kill experiments, colony count decreases were
26 isolate- and concentration-dependent at 0.25, 1, 4, 8,
27 16 and 32 mg/L in RPMI-1640, but concentration-
28 independent at 1, 4, 8, 16 and 32 mg/L in 50 % serum.
29 One-hour caspofungin exposure at 4, 16 and 32 mg/L
30resulted in CFU decreases comparable with the results
31obtained in time-kill experiments in RPMI-1640, but
3250 % serum at 4, 16 and 32 mg/L allowed growth of
33all isolates (k values were negative) (P\ 0.05–0.001).
34PAFE in 50 % serum decreased markedly at 4, 16 and
3532 mg/L. Killing rates remained high and concentra-
36tion-independent in 50 % serum in case of continuous
37but not in case of brief caspofungin exposure. As only
38a short growth inhibition without killing was observed
39in 50 % serum, clinical relevance of caspofungin
40PAFE in vivo is questionable.
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43Introduction
44Echinocandins (caspofungin, micafungin and anidu-
45lafungin) are reported to exhibit concentration-depen-
46dent fungicidal or fungistatic activity against the
47majority of Candida species. Additionally, echino-
48candins exert prolonged postantifungal effect (PAFE)
49after short (1 h) echinocandin exposure against many
50Candida species, including C. parapsilosis [1–4].
51Recent in vitro findings with RPMI-1640 suggest that
52a very short (B1 h) exposure to caspofungin kills
53Candida cells as effectively as a continuous 24-h
54exposure [5]. As echinocandins are highly protein-
55bound (C96.5 %) agents (i.e., serum fundamentally
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56 influences killing activities of echinocandins) [6–8],
57 we compared killing rates produced by short (1 h) and
58 continuous (24 h) caspofungin exposure as well as
59 PAFE in RPMI-1640 and 50 % serum against C.
60 albicans.
61 Materials and Methods
62 Isolates
63 All C. albicans originated from blood samples
64 (Table 1) and were identified as described previously
65 [9]. ATCC 10231 and an echinocandin-resistant
66 isolate (DPL20, FKS F645P) were also included in
67 the study.
68 MIC Determination
69 Caspofungin (Sigma, Budapest, Hungary) MICs in
70 RPMI-1640 with and without 50 % human serum
71 (from a human male, type AB, Sigma, Budapest,
72 Hungary) were determined using the CLSI broth
73 macrodilution method [6–8, 10]. Caspofungin final
74 concentration ranged between 0.015 and 32 mg/L.
75 MICs were read after 24 h using the partial inhibition
76 criterion [10].
77 Postantifungal Effect and Time-Kill Curves
78 PAFEwas measured in both media simultaneously. As
79 in our preliminary experiments 5-, 10- and 30-min
80 exposures to 0.5, 1 or 2 mg/L caspofungin did
81 not produce measurable PAFEs in 50 % serum
82(1–16 9 MIC in 50 % serum), we used caspofungin
83at 4, 16 and 32 mg/L concentrations with a 60-min
84exposure time (brief caspofungin exposure) [3–5]. As
85the maximum administrable daily 150–200 mg ca-
86spofungin doses produce 30.4–40.6 mg/L geometric
87mean of peak concentrations in humans [11], the
88highest caspofungin concentration used in this study
89was 32 mg/L [6].
90The starting inocula in PAFE experiments were
911–5 9 10
5 cells/ml [3–5]. After 1 h, the cells were
92collected by centrifugation at 1.5009g for 10 min and
93were washed three times with sterile saline, resus-
94pended in 10 ml drug-free warm RPMI-1640 with and
95without 50 % human serum. Samples (100 ll) were
96removed at 0, 4, 8, 12 and 24 h, serially diluted
97tenfold, plated (4 9 30 ll) onto Sabouraud dextrose
98agar and incubated at 35 C for 48 h [3–5].
99For time-kill assays (continuous 24-h caspofungin
100exposure), test solutions were not centrifuged or
101washed. We used 0.25, 1, 4, 8, 16 and 32 mg/L
102caspofungin. In case of isolate DPL20, we used 4, 8,
10316 and 32 mg/L caspofungin. Otherwise, the method
104was the same as described for PAFE [3–5]. All
105experiments were performed at least twice, and means
106of data are presented.
Table 1 Candida albicans isolates, MICs of caspofungin and the effect caspofungin in time-kill studies in RPMI-1640 (RPMI) and
RPMI-1640 supplemented with 50 % serum (50 % serum)
Isolates MIC (mg/L) Effect in time-kill studies at concentrations shown (mg/L)
RPMI 50 % Serum RPMI 50 % Serum
183 0.03 0.25 C0.03 fungistatic C0.25 fungistatic
3666 0.03 0.125 C0.03 fungistatic C0.25 fungistatic
12132 0.015 0.25 C0.03 fungistatic C0.25 fungistatic
10920 0.03 0.125 C0.03 fungistatic C0.25 fungistatic
ATCC 10231 0.03 0.5 C0.03 fungistatic C0.5 fungistatic
DPL20 4 [32 C16 fungistatic No effect
cFig. 1 Time-kill plots of caspofungin against four Candida
albicans isolates (averages ± standard deviation) in RPMI-
1640 (a) and 50 % serum (d) against ATCC 10231 type strain in
RPMI-1640 (b) and 50 % serum (e), and against the echino-
candin-resistant C. albicansDPL20 in RPMI-1640 (c) and 50 %
serum (f). Clinical isolates and type strain were exposed to 0.25,
1, 4, 8, 16 and 32 mg/L, while DPL20 isolate was exposed to 4,
8, 16 and 32 mg/L of caspofungin for 24 h (continuous
caspofungin exposure)
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107 Data Analysis
108 Killing kinetics was analyzed mathematically, as
109 described previously [6, 12]. An exponential equation
110 was fitted to the mean data at each time point:
111 Nt = N0 9 e
-kt, where Nt is the number of viable
112 yeasts at time t,N0 is the number of viable yeasts in the
113initial inoculum, k is the killing rate and t is the
114incubation time. Negative k values indicate growth,
115and positive k values indicate killing. The goodness of
116fit for each isolate was assessed by the r
2 value ([0.8)
117[6, 12]. PAFE was defined as the difference between
118the time required for control and test isolates to grow 1
119log10 following drug removal [3–5].
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Fig. 2 Postantifungal effect curves of caspofungin against
Candida albicans isolate 183 in RPMI-1640 (a) and 50 % serum
(c), and against C. albicans isolate 3666 in RPMI-1640 (b) and
50 % serum (d). Isolates were exposed to 4, 16 and 32 mg/L of
caspofungin for 1 h (brief caspofungin exposure)
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120 One-way ANOVA with Tukey’s posttesting was
121 used to analyze differences in killing rates by
122 concentrations in either RPMI-1640 or 50 % serum
123 [6]. Paired T test was used to compare the effect of the
124 medium as well as the killing and growth rates in time-
125 kill and PAFE experiments at the same drug
126 concentration.
127Results
128Susceptibility
129MIC values are presented in Table 1. Paradoxical
130growth was not observed. Clinical isolates and 10231
131ATCC strain were susceptible to caspofungin
Table 2 Postantifungal effect (PAFE) of caspofungin against Candida albicans isolates at 4, 16 and 32 mg/L in RPMI-1640 (RPMI)
and RPMI-1640-50 % serum (50 % serum)
Isolate number Medium PAFE in hours
4 (mg/L) 16 (mg/L) 32 (mg/L)
183 RPMI-1640 [19.34 [19.34 14.81
50 % Serum 2.27 10.14 [18.79
3666 RPMI-1640 7.40 [19.23 [19.23
50 % Serum 0 0.79 1.01
10920 RPMI-1640 [19.05 [19.05 [19.05
50 % Serum 0 0.24 0.24
12132 RPMI-1640 14.21 13.84 7.65
50 % Serum 0.60 0.95 3.46
ATCC 10231 RPMI-1640 4.89 [19.88 [19.88
50 % Serum 0.09 0.34 1.39
DPL20 RPMI-1640 0 0 0
50 % Serum 0 0 0
Table 3 Maximum log changes in log CFU/mL compared to starting inoculum in time-kill and postantifungal (PAFE) studies in
RPMI-1640 and RPMI-1640-50 % serum (50 % serum)
Isolate number Media Maximum log decreases in CFU in time-killing and PAFE experiments at the indicated caspofungin
concentration
4 mg/L 16 mg/L 32 mg/L
Time kill PAFE Time kill PAFE Time kill PAFE
183 RPMI-1640 -1.1 -0.53 -1.18 -0.42 -0.75 -0.48
50 % serum -1.06 ?0.37 -0.9 -0.08 -0.9 -0.04
3666 RPMI-1640 -1.38 -0.66 -0.54 -1.6 -0.34 -2.08
50 % serum -1.40 ?0.13 -1.12 ?0.12 -2.68 -0.12
10920 RPMI-1640 -1.23 -1.23 -1.22 -1.48 -0.69 -1.48
50 % serum -0.69 ?0.49 -1.46 ?0.38 -1.43 ?0.64
12132 RPMI-1640 -0.44 -0.30 -0.19 -0.27 -0.23 -0.62
50 % serum -1.56 ?0.67 -1.71 ?0.66 -1.86 ?0.27
ATCC 10231 RPMI-1640 -1.56 -1.48 -0.55 -2.08 -1.65 -1.78
50 % serum -1.18 ?0.26 -1.38 ?0.09 -1.95 ?0.08
DPL20 RPMI-1640 -0.39 ?0.61 -1.19 ?0.78 -1.00 ?0.37
50 % serum ?0.81 ?0.84 ?0.69 ?0.57 -0.05 ?0.71
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F132 according to the revised CLSI break points in RPMI-
133 1640 [13]. As expected, the DPL20 isolate with a
134 prominent fks mutation was resistant to caspofungin
135 [13]. MIC values were 4- to 16-fold higher in the
136 presence of 50 % serum.
137 Time-Kill Experiments
138 In time-kill experiments, caspofungin was fungistatic
139 at C1–29 MIC in both media against the clinical
140 isolates as well as against the 10231 ATCC strain
141 (\99.9 % reduction in viable cell count compared to
142 the starting inoculum) (Table 1; Fig. 1a, b, d, e).
143 Against the resistant strain DPL20, caspofungin
144 produced a weak fungistatic effect in RPMI-1640
145 (Fig. 1C). In 50 % serum, the killing curves were
146 generally similar to control; at 32 mg/L, a negligible
147 reduction was observed after 4 h, but later the killing
148 curves again became similar to control (Fig. 1f).
149 Postantifungal Effect
150 The time required for control (drug-free) isolates to
151 grow 1 log10was similar in both media (4.12–4.95 h in
152 RPMI-1640 and 4.69–5.17 h in 50 % serum). PAFE
153 plots for isolates 183 and 3666 in RPMI-1640 and in
154 50 % serum are shown in Fig. 2. In RPMI-1640,
155 clinical isolates and the ATCC 10231 strain showed
156 the inhibition of re-growth at 4, 16 and 32 mg/L for
157 4.89 to[19.34, 13.84 to[19.88 and 7.65 to[19.88 h,
158 respectively (Table 2). PAFE in 50 % serum
159 decreased markedly at 4, 16 and 32 mg/L concentra-
160 tions (Table 2; Fig. 2). Most isolates showed growth
161 in 50 % serum; colony count decreases occurred only
162 in cases of isolates 183 at 16 and 32 mg/L (Fig. 2c)
163 and 3666 at 32 mg/L (Fig. 2d) and only after 4 h and
164 were negligible (Table 3). In case of DPL20, isolate
165 PAFE was never observed regardless of media
166 (Table 2).
167Comparison of Colony Count Changes in Time-
168Kill and Postantifungal Effect Experiments
169Maximum colony count changes compared to the
170starting inocula in time-kill and PAFE experiments at
1714, 16 and 32 mg/L are presented in Table 3.
172Comparing the different media at the same con-
173centrations in killing experiments, the CFU decrease
174was generally higher in 50 % serum than in RPMI-
1751640 (Table 3). Contrastingly, the CFU decrease in
176PAFE experiments was significantly higher in RPMI-
1771640 than in 50 % serum with all isolates and
178concentrations (P\ 0.05–0.001) (Table 3).
179Comparing the colony counts reductions at the
180same concentrations in PAFE and time-kill experi-
181ments, we noticed comparable or sometimes higher
182reductions (in cases of 10920 and 3666 isolates) in
183PAFEs than that seen with continuous 24-h exposure
184in RPMI-1640 (Table 3). However, 50 % serum
185significantly decreased the PAFE killing for all tested
186isolates (P\ 0.01–0.001) (Table 3; Fig. 4a–e).
187Killing Rates in Time-Kill Experiments
188In time-kill experiments, killing activity of caspofun-
189gin was significantly weaker at 16–32 mg/L than at
1900.25, 1, 4 and 8 mg/L (P\ 0.05–0.001) in RPMI-
1911640 (mini-paradoxical effect) (Fig. 3a). However,
192killing rates at 1–32 mg/L were concentration-inde-
193pendent in 50 % serum against the susceptible isolates
194(Fig. 3d). Similar effect was noticed in case of the
195strain ATCC 10231 (Fig. 3c, f). In case of isolate,
196DPL20 k values were negative (indicating the growth
197instead of killing) regardless of media (Fig. 3b, e).
198Killing Rates in Postantifungal Effect Experiments
199In PAFE experiments, killing rates for clinical isolates
200and the ATCC strain in RPMI-1640 were isolate- and
201concentration-dependent (k values from -0.111 to
202?1.019 1/h), while in 50 % serum, the k values
203showed markedly narrower range (from -0.017 to -
2040.185 1/h) (Fig. 4a–e).
205Discussion
206This study is the first in which killing rates in short and
207continuous caspofungin exposures to C. albicanswere
bFig. 3 Killing rates of caspofungin and the corresponding fitted
regression lines (dashed lines) in time-kill experiments against
four C. albicans isolates (averages ± standard deviation) in
RPMI-1640 (a) and 50 % serum (d), against C. albicansDPL20
in RPMI-1640 (b) and 50 % serum (e), and against ATCC
10231 type strain in RPMI-1640 (c) and 50 % serum (f).
Positive and negative k values indicate the decrease and
increase, respectively, in viable cell numbers
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F208 compared head to head in RPMI-1640 with and
209 without 50 % serum. In agreement with previous
210 results [3–5], the CFU decreases in time-kill and
211 PAFE experiments were similar in RPMI-1640;
212 however, at 16 and 32 mg/L, killing rates decreased.
213 Decreased killing rates in time-kill experiments at 16
214 and 32 mg/L can be explained by the adaptive and
215 compensatory response to high caspofungin concen-
216 trations in the fungal cells that limit killing effect and
217 allow for the growth [14]. Addition of 50 % serum
218 significantly decreased killing rates at 4, 16 and
219 32 mg/L in the PAFE experiments as compared to
220 RPMI-1640, while the killing rates in time-kill
221 experiments (continuous exposure) at C1 mg/L con-
222 centrations remained high and concentration-indepen-
223 dent (i.e., killing rate reached its maximum at 1 mg/L).
224 These findings are in accordance with our previous
225 results, where killing rates of C. krusei and C.
226 inconspicua did not differ significantly in 50 % serum
227 at effective concentrations [6]. Moreover, 1-h expo-
228 sure ofC. albicans to 0.5, 1 and 2 mg/L of caspofungin
229 in 50 % serum is not long enough to produce any
230 growth inhibition, as opposed to what found with
231 RPMI-1640 alone.
232 Louie et al. [15] demonstrated that tissues serve as
233 drug reservoirs fromwhich the drug is released slowly,
234 explaining that serum caspofungin half-life tripled
235 when both serum and tissues half-life were taken into
236 account in the terminal half-life calculation. They
237 concluded that the primary tissue reservoir rather than
238 PAFE was responsible for the excellent in vivo
239 activity of caspofungin [15]. Their results are in line
240 with the present study, as 1-h exposure to caspofungin
241 produced negative k values (growth) and significantly
242 decreased PAFEs in 50 % serum.
243 PAFE is frequently regarded as a contributor to
244 clinical efficacy of echinocandins [1–4, 13]. It is
245 defined as prolonged growth inhibition following
246 limited (generally 1 h) in vitro drug exposure; how-
247 ever, it must be noted that this is not equal to killing, as
248slower growth may also be regarded as prominent
249PAFE. While killing may directly lead to eradication,
250growth, even slower growth, of fungi still carries a risk
251of persistent infection and fungal re-growth. These
252facts should be taken into consideration when trans-
253lating PAFE as a contributor to clinical efficacy.
254Present results strongly suggest that PAFE is lost in the
255presence of 50 % serum, even though marked PAFE is
256detected in RPMI-1640 after 5-min exposure [5]. The
257negligible PAFEs found in 50 % serum indicate that
258prolonged in vitro PAFEs (in RPMI-1640), frequently
259interpreted as a contributor to better clinical efficacy
260[1–4], may be less important in vivo (better mimicked
261by the serum-containing medium) at least against C.
262albicans. Whether these also apply for non-albicans
263species is to be answered by further studies.
264In summary, continuous but not brief caspofungin
265exposure produced measurable killing rates against C.
266albicans clinical isolates in killing studies in the
267presence of 50 % serum. PAFE after brief exposure to
268caspofungin (and probably to other echinocandins),
269even when marked, may play a limited role in the
270excellent clinical efficacy of echinocandins.
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